Drugs / Interferon Alpha-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05756166 | Feb 2024 → Apr 2025 | female breast carcinoma, triple-negative breast carcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon Alpha-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05756166 ↗ |
| Modality | Protein / enzyme biologic | “IFNA2 Protein” NCT05756166 ↗ |
| Route | Intravenous | “interferon alpha-2b IV” NCT05756166 ↗ |